North America Zika Virus Vaccines Market Report

North America Zika Virus Vaccines Market Size

The North American Zika Virus Vaccines Market is estimated to grow from USD 7.00 billion in 2024 to USD 10.47 billion in 2033, representing a CAGR of 4.58%.

The rising number of research centers in the biotechnology field is mainly driving the demand in the market. Growing incidences of transmitted diseases and demand to develop new drugs and vaccines in pharmaceutical companies are expanding the market's growth rate to some extent. Zika virus may affect pregnant women and taking the vaccines may help the women to not lead to further complications. The aforementioned factor is also propelling the demand for the North American Zika virus vaccine market. Growing awareness of the availability of these vaccines through digital advertisements is additionally accelerating the growth rate of the market tremendously.

However, fluctuations in the availability of raw materials, which eventually increase the prices of the final product are slightly impeding the demand for the zika virus vaccines in North America. Stringent rules and regulations by the government in approving new products are a challenge for the market developers. Along with this, the lack of complete knowledge over the availability of vaccines in rural areas is hindering the growth rate of the market in North America. The dearth of skilled people in manufacturing quality vaccines in some areas is also a factor limiting the demand in the market.

Growing focus on the development of innovative drugs and vaccines with the latest technology at affordable prices is lucratively anticipated to create growth opportunities for the market. Favorable conditions from the government by changing schemes to provide better treatment procedures for the common people are likely to outshine the demand of the market in North America. Besides, the rising scale of healthcare centers with pharmaceutical companies is expanding the demand for the zika virus vaccine market. Creating awareness through campaigns in rural areas by both private and public agencies to promote healthy living and reduce the risk from the zika virus by taking proper treatment in time is expected to bolster the demand of the market in North America.

Regionally, the North America region has a substantial CAGR due to the presence of a wide range of pharmaceutical companies and their high investments in the healthcare sector and favorable reimbursements in the healthcare sector.

KEY MARKET PLAYERS

Noteworthy companies operating in the North America Zika virus vaccines market profiled in this report are Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., Immunovaccine Inc., GeneOne Life Science Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Bharat Biotech International Ltd., Hawaii Biotech Inc., and Sanofi S.A.

MARKET SEGMENTATION

This research report on the North American Zika Virus Vaccines Market has been segmented & sub-segmented into the following categories:

By Type

• Therapeutic Vaccines
• Preventive Vaccines

By End-User

• Hospitals
• Clinics
• Research Institutes
• Others

By Country

• The United States
• Canada
• Rest of North America